These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22328585)

  • 21. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
    Geyer J; Gavrilova O; Petzinger E
    J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
    Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
    Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
    Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Subcutaneous and Intraperitoneal Administration Methods to Facilitate Cassette Dosing in Microdialysis Studies in Rats.
    Durk MR; Deshmukh G; Valle N; Ding X; Liederer BM; Liu X
    Drug Metab Dispos; 2018 Jul; 46(7):964-969. PubMed ID: 29700231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats.
    Huang L; Li X; Roberts J; Janosky B; Lin MH
    Xenobiotica; 2015; 45(6):547-55. PubMed ID: 25539457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
    Oberoi RK; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.
    Zhou S; Zong Y; Lu T; Sorrentino BP
    Biotechniques; 2003 Dec; 35(6):1248-52. PubMed ID: 14682060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the utility of brain slice methods to study brain penetration.
    Becker S; Liu X
    Drug Metab Dispos; 2006 May; 34(5):855-61. PubMed ID: 16501003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
    Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
    J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.
    Uhr M; Steckler T; Yassouridis A; Holsboer F
    Neuropsychopharmacology; 2000 Apr; 22(4):380-7. PubMed ID: 10700657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
    Enokizono J; Kusuhara H; Ose A; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2008 Jun; 36(6):995-1002. PubMed ID: 18322075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Hoque MT; Kis O; De Rosa MF; Bendayan R
    Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
    Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.
    Doran A; Obach RS; Smith BJ; Hosea NA; Becker S; Callegari E; Chen C; Chen X; Choo E; Cianfrogna J; Cox LM; Gibbs JP; Gibbs MA; Hatch H; Hop CE; Kasman IN; Laperle J; Liu J; Liu X; Logman M; Maclin D; Nedza FM; Nelson F; Olson E; Rahematpura S; Raunig D; Rogers S; Schmidt K; Spracklin DK; Szewc M; Troutman M; Tseng E; Tu M; Van Deusen JW; Venkatakrishnan K; Walens G; Wang EQ; Wong D; Yasgar AS; Zhang C
    Drug Metab Dispos; 2005 Jan; 33(1):165-74. PubMed ID: 15502009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
    Chen C; Lin J; Smolarek T; Tremaine L
    Drug Metab Dispos; 2007 Oct; 35(10):1725-9. PubMed ID: 17640956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
    Dagenais C; Zong J; Ducharme J; Pollack GM
    Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.